ReviewJournal of clinical laboratory analysis2026
Remarkable Prolongation of Irreversible APTT and Non-Significant Hemorrhage: A Rare High Titer of FVIII Inhibitor Case Report and Literature Review.
Review in Journal of clinical laboratory analysis, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
backgroundAcquired hemophilia A (AHA) is a rare hemorrhagic disease characterized by isolated prolongation of activated partial thromboplastin time (aPTT) and existence of autoantibodies against factor VIII (FVIII).
methodsHere, we present a patient with subcutaneous hemorrhage and remarkable prolongation of irreversible aPTT.
resultsFurther laboratory testing revealed reduced activity of multiple coagulation factors; this finding was subsequently identified as an artifact caused by the high-titer FVIII inhibitor, confirmed through dilution studies. Despite the high inhibitor titer and the presence of bleeding manifestations, specific anti-hemorrhagic therapy was not required for this patient. Following 6 months of immunosuppressive treatment, the patient achieved resolution of ecchymosis and maintained normal coagulation factor activity. Throughout the 12-month follow-up period, the patient ultimately died from disease progression under palliative support.
conclusionIn all, this study demonstrated atypical characteristics of an AHA patient and emphasized that the treatment strategy should be guided by clinical manifestation rather than testing results solely.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.